using glp 1 New Guidelines on GLP-1 Drugs for Obesity Released Part 2 of a 3-Part

20% of patients with NASH develop cirrhosis and have a high risk of hepatocarcinoma

Thus far it appears to me that the signals are on the positive side, meaning that these drugs seem to be pretty safe as we follow them over increasing amounts of time. ******* Ralph A

At 72 her silhouette reflects a $0.70$ waist-to-hip ratio which is the biological ideal for feminine aesthetics

The Food and Drug Administration (FDA) has approved three GLP-1s for obesity-related treatment, including Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide)

doi: 10.1038/304368a0 14 HansenLDeaconCFOrskovCHolstJJ

Higher doses may improve outcomes in this group, though specific data for the 7.2mg dose in type 2 diabetes is still emerging